The role of circulating free DNA in the management of NSCLC

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Introduction: Circulating cell-free DNA (cfDNA) testing has emerged as an alternative to tumor tissue analyses for the management of metastatic non-small-cell lung cancer (NSCLC) patients. Analysis of cfDNA is a minimally invasive procedure that might better reflect tumor heterogeneity and allows repeated testing over the time. Areas covered: This review article covers the different applications of cfDNA testing in NSCLC: early diagnosis of the disease; detection of minimal residual disease in early lung cancer; identification of predictive and prognostic markers in advanced NSCLC patients; monitoring the response to therapy; assessment of tumor mutation burden. Expert commentary: The use of liquid biopsy is rapidly expanding to different applications. The combination of different circulating biomarkers (cfDNA, protein, miRNA) might improve the sensitivity and specificity of this approach in patients with low tumor burden. cfDNA testing is representing a valid source for molecular profiling in management of metastatic NSCLC patients and is providing important knowledge on tumor heterogeneity. Clinical trials are needed in order to transfer the information deriving from liquid biopsy testing in new therapeutic strategies.

Original languageEnglish
Pages (from-to)19-28
Number of pages10
JournalExpert Review of Anticancer Therapy
Volume19
Issue number1
DOIs
Publication statusPublished - Jan 2 2019

Fingerprint

Non-Small Cell Lung Carcinoma
DNA
Tumor Burden
Biopsy
Neoplasms
Residual Neoplasm
MicroRNAs
Early Diagnosis
Lung Neoplasms
Biomarkers
Clinical Trials
Sensitivity and Specificity
Mutation
Therapeutics
Proteins

Keywords

  • biomarkers
  • cfDNA
  • Liquid biopsy
  • next generation sequencing
  • non-small-cell lung cancer
  • tumor genotyping

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Cite this

@article{aeb69761bdd6411cb038f424dfb4fd81,
title = "The role of circulating free DNA in the management of NSCLC",
abstract = "Introduction: Circulating cell-free DNA (cfDNA) testing has emerged as an alternative to tumor tissue analyses for the management of metastatic non-small-cell lung cancer (NSCLC) patients. Analysis of cfDNA is a minimally invasive procedure that might better reflect tumor heterogeneity and allows repeated testing over the time. Areas covered: This review article covers the different applications of cfDNA testing in NSCLC: early diagnosis of the disease; detection of minimal residual disease in early lung cancer; identification of predictive and prognostic markers in advanced NSCLC patients; monitoring the response to therapy; assessment of tumor mutation burden. Expert commentary: The use of liquid biopsy is rapidly expanding to different applications. The combination of different circulating biomarkers (cfDNA, protein, miRNA) might improve the sensitivity and specificity of this approach in patients with low tumor burden. cfDNA testing is representing a valid source for molecular profiling in management of metastatic NSCLC patients and is providing important knowledge on tumor heterogeneity. Clinical trials are needed in order to transfer the information deriving from liquid biopsy testing in new therapeutic strategies.",
keywords = "biomarkers, cfDNA, Liquid biopsy, next generation sequencing, non-small-cell lung cancer, tumor genotyping",
author = "{Esposito Abate}, Riziero and Raffaella Pasquale and Francesca Fenizia and Rachiglio, {Anna Maria} and Cristin Roma and Francesca Bergantino and Laura Forgione and Matilde Lambiase and Alessandra Sacco and Piccirillo, {Maria Carmela} and Alessandro Morabito and Nicola Normanno",
year = "2019",
month = "1",
day = "2",
doi = "10.1080/14737140.2019.1548938",
language = "English",
volume = "19",
pages = "19--28",
journal = "Expert Review of Anticancer Therapy",
issn = "1473-7140",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - The role of circulating free DNA in the management of NSCLC

AU - Esposito Abate, Riziero

AU - Pasquale, Raffaella

AU - Fenizia, Francesca

AU - Rachiglio, Anna Maria

AU - Roma, Cristin

AU - Bergantino, Francesca

AU - Forgione, Laura

AU - Lambiase, Matilde

AU - Sacco, Alessandra

AU - Piccirillo, Maria Carmela

AU - Morabito, Alessandro

AU - Normanno, Nicola

PY - 2019/1/2

Y1 - 2019/1/2

N2 - Introduction: Circulating cell-free DNA (cfDNA) testing has emerged as an alternative to tumor tissue analyses for the management of metastatic non-small-cell lung cancer (NSCLC) patients. Analysis of cfDNA is a minimally invasive procedure that might better reflect tumor heterogeneity and allows repeated testing over the time. Areas covered: This review article covers the different applications of cfDNA testing in NSCLC: early diagnosis of the disease; detection of minimal residual disease in early lung cancer; identification of predictive and prognostic markers in advanced NSCLC patients; monitoring the response to therapy; assessment of tumor mutation burden. Expert commentary: The use of liquid biopsy is rapidly expanding to different applications. The combination of different circulating biomarkers (cfDNA, protein, miRNA) might improve the sensitivity and specificity of this approach in patients with low tumor burden. cfDNA testing is representing a valid source for molecular profiling in management of metastatic NSCLC patients and is providing important knowledge on tumor heterogeneity. Clinical trials are needed in order to transfer the information deriving from liquid biopsy testing in new therapeutic strategies.

AB - Introduction: Circulating cell-free DNA (cfDNA) testing has emerged as an alternative to tumor tissue analyses for the management of metastatic non-small-cell lung cancer (NSCLC) patients. Analysis of cfDNA is a minimally invasive procedure that might better reflect tumor heterogeneity and allows repeated testing over the time. Areas covered: This review article covers the different applications of cfDNA testing in NSCLC: early diagnosis of the disease; detection of minimal residual disease in early lung cancer; identification of predictive and prognostic markers in advanced NSCLC patients; monitoring the response to therapy; assessment of tumor mutation burden. Expert commentary: The use of liquid biopsy is rapidly expanding to different applications. The combination of different circulating biomarkers (cfDNA, protein, miRNA) might improve the sensitivity and specificity of this approach in patients with low tumor burden. cfDNA testing is representing a valid source for molecular profiling in management of metastatic NSCLC patients and is providing important knowledge on tumor heterogeneity. Clinical trials are needed in order to transfer the information deriving from liquid biopsy testing in new therapeutic strategies.

KW - biomarkers

KW - cfDNA

KW - Liquid biopsy

KW - next generation sequencing

KW - non-small-cell lung cancer

KW - tumor genotyping

UR - http://www.scopus.com/inward/record.url?scp=85058737930&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058737930&partnerID=8YFLogxK

U2 - 10.1080/14737140.2019.1548938

DO - 10.1080/14737140.2019.1548938

M3 - Review article

VL - 19

SP - 19

EP - 28

JO - Expert Review of Anticancer Therapy

JF - Expert Review of Anticancer Therapy

SN - 1473-7140

IS - 1

ER -